Ironwood Pharmaceuticals (IRWD) Depreciation & Amortization (CF) (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Depreciation & Amortization (CF) across 17 years of filings, most recently posting $443000.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $443000.0, down 7.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 million (down 6.68% YoY), and the FY2025 annual result was $1.1 million, down 8.33% from the prior year.
• Depreciation & Amortization (CF) came in at $443000.0 for Q1 2026 at Ironwood Pharmaceuticals, down from $460000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $513000.0 in Q1 2024 to a low of $270000.0 in Q2 2023.
• The 5-year median for Depreciation & Amortization (CF) is $467000.0 (2025), against an average of $431058.8.
• Across the five-year window, Depreciation & Amortization (CF) retreated 25.0% in 2023 and soared 87.41% in 2024, its largest moves.
• Ironwood Pharmaceuticals' Depreciation & Amortization (CF) stood at $340000.0 in 2022, then soared by 50.59% to $512000.0 in 2023, then fell by 5.27% to $485000.0 in 2024, then declined by 5.15% to $460000.0 in 2025, then fell by 3.7% to $443000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $443000.0 (Q1 2026), $460000.0 (Q4 2025), and $475000.0 (Q3 2025), per Business Quant data.